AngioDynamics Posts Record Revenue Growth Amid Strategic Shift — AngioDynamics, Inc.

Event summary

AngioDynamics reported fiscal year 2026 revenue of $320.2 million, up 9.4% YoY, with Med Tech segment growing 18.4%.
Med Device net sales increased by 2.5%, while gross margin improved to 54.6% from 53.9%.
The company ended the year with $53.9 million in cash and a debt-free balance sheet.
FDA approved IDE for RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia.
Palmetto GBA finalized Medicare coverage for NanoKnife IRE procedures, effective July 5, 2026.

The big picture

AngioDynamics' strategic transformation toward Med Tech is driving record revenue growth, with the segment now representing 47% of total revenue. The company's focus on innovative platform technologies in cardiology and interventional oncology positions it well in fast-growing global markets. However, managing tariff-related expenses and sustaining operational discipline will be key to maintaining profitability.

What we're watching

Revenue Mix Shift: The pace at which AngioDynamics can shift its revenue mix toward higher-growth, higher-margin Med Tech platforms will be critical for sustained profitability.
Regulatory Approvals: The success of ongoing clinical trials and regulatory approvals for key products like NanoKnife and AlphaVac will drive future adoption and market expansion.
Operational Efficiency: How effectively AngioDynamics manages tariff-related headwinds and manufacturing transitions will impact its ability to maintain gross margins.